Thursday, July 31, 2025

DRUG - Betashares Global Healthcare Currency Hedged ETF

 

Why the Betashares Global Healthcare ETF – Currency-Hedged (ASX: DRUG) has slipped in 2025

Factor What’s happening Evidence
1. Under-performing global healthcare stocks The sector has lagged broad equity benchmarks this year (-0.6 % YTD vs the S&P 500’s +8 %). Big-pharma names such as Pfizer, Johnson & Johnson and Roche – together almost half of DRUG’s portfolio – have been pressured by drug-price politics, looming patent-cliffs and faltering obesity-drug pipelines. Bloomberg sector table (Bloomberg.com); FT coverage of drug-price crackdown & patent-cliff worries (Financial Times, Financial Times)
2. Currency-hedging drag DRUG hedges USD, EUR, CHF etc. back to AUD. With the Aussie dollar up ~5 % YTD vs USD the hedge has worked (it shielded you from a stronger AUD), but it incurred a carry cost because US cash rates (≈ 5 ½ %) are still above Aussie rates (≈ 4 ¼ %). That negative “forward-points” cost is taken out of fund returns each day. AUD spot +5.22 % YTD (Bloomberg.com); hedging mechanics in Betashares factsheet (uses daily forwards) (Betashares)
3. Large mid-year distribution On 1 July 2024 the fund went ex-distribution for A$0.223 per unit and again (smaller) on 2 Jan 2025. Price charts that ignore reinvested cash make the drop look steeper than the total-return reality. Distribution history table (Market Index)
4. Higher fees than peers At 0.57 % p.a. DRUG’s management cost is > IXJ (0.43 %) or VHT (0.47 %). In a flat market fees bite more. Key-facts section (Betashares)

Taken together, these explain why the unit price has slipped from A$8.81 (30 Jun 2024 close) to A$7.47 NAV (31 Jul 2025) – roughly -15 % on price, or -12 % total-return after adding back cash payouts. (Market Index)


Is it a good entry point?

Lens What it tells us now
Valuation MSCI World Healthcare forward P/E ≈ 15.9× vs its 10-yr average ~18× – the sector is not “cheap”, but it has de-rated to a post-COVID low. (MSCI)
Macro backdrop Healthcare is defensive, yet 2025 rate-cut hopes have pushed investors back into cyclicals and tech. A US election season with heavy drug-price rhetoric could keep a lid on multiples until November.
Currency view If you expect the AUD to stay firm or rise, the hedged class limits FX noise. If you think the AUD could fall back below US $0.65, the un-hedged IXJ ETF may rebound faster.
Sector catalysts • US FDA decisions on GLP-1 obesity drugs (benefits Lilly/Novo, hurts others). • M&A pick-up as big-pharma reloads pipelines before 2028 patent cliffs. • Possible easing of US drug-price rhetoric after the election.

Bottom line

Pros

  • Diversified exposure to >100 global healthcare giants in a single ASX trade.

  • Currency hedge shelters you from AUD swings.

  • Sector trading at a discount to its own 10-year average.

Cons

  • Negative hedge carry (~0.6-0.8 % p.a.) plus 0.57 % fee.

  • Political overhang on drug pricing could extend through the US election.

  • Portfolio heavily concentrated in mega-cap pharma that are currently out of favour.

Long-term investors (3-5 yr horizon): a reasonable accumulation point if you want defensive, ageing-population exposure and prefer to keep currency risk minimal. Dollar-cost-averaging can soften further volatility.
Tactical traders (6-12 mo): momentum remains weak (Investing.com technical signal = “Strong Sell”) (Investing.com Australia); waiting for a clear price base, or buying the un-hedged IXJ if you expect AUD weakness, may offer better risk/reward.

(Always consider your own goals and talk to a licensed adviser before acting.)


Quick checklist before buying

  1. Strategy fit – does a single-sector ETF suit your diversification plan?

  2. Hedged vs un-hedged – outlook for AUD over your holding period.

  3. Fee drag – 0.57 % plus hedging cost; total ~1.2 % in a flat year.

  4. Re-invest distributions – to capture total return, not just price.

  5. Position size & risk limits – healthcare ≈ 12 % of MSCI World; keeping DRUG around that weight avoids concentration risk.

Need a side-by-side sheet comparing DRUG with IXJ (un-hedged) and VHT (global healthcare un-hedged via Vanguard)? Let me know and I can spin up a quick table or tracker.

Wednesday, July 9, 2025

Semiconductor ETF - ASX

 

If you're seeking exposure to the semiconductor sector through an ETF listed on the ASX, the Global X Semiconductor ETF (ASX) is currently the primary option available.(bestetfs.com.au)


🔹 Global X Semiconductor ETF (ASX:SEMI)

  • Objective: Tracks the Solactive Global Semiconductor 30 Index, providing exposure to 30 of the world's leading semiconductor companies.

  • Top Holdings: Includes major players like Taiwan Semiconductor Manufacturing Company, Broadcom, NVIDIA, ASML, and AMD.

  • Management Fee: 0.45% p.a.

  • Assets Under Management: Approximately A$350 million as of June 2025.

  • Dividend Yield: Around 3.4%, with semi-annual distributions.

  • Performance: Delivered a 1-year return of 6.09% and an average annual return of 19.71% since inception in August 2021.(Listcorp, Stock Analysis, globalxetfs.com.au, InvestSMART)

This ETF offers diversified exposure to the global semiconductor industry, encompassing companies involved in chip design, manufacturing, and related technologies.


🔹 Alternative ASX ETFs with Indirect Semiconductor Exposure

While not exclusively focused on semiconductors, the following ETFs provide indirect exposure through broader technology investments:(globalxetfs.com.au)

  • BetaShares S&P/ASX Australian Technology ETF (ASX:ATEC): Tracks the S&P/ASX All Technology Index, which includes Australian tech companies, some of which may be involved in semiconductor-related activities.

  • BetaShares Global Robotics and Artificial Intelligence ETF (ASX:RBTZ): Invests in global companies involved in robotics and AI, sectors that heavily rely on semiconductor technologies.

  • BetaShares Asia Technology Tigers ETF (ASX:ASIA): Provides exposure to leading Asian technology companies, many of which are significant players in the semiconductor industry.

These ETFs offer broader technology sector exposure, which includes, but is not limited to, semiconductor companies.



ASX Returns = (CAGR) over the past 30 years

According to long-term data from Vanguard, an investment into a simple, diversified basket of local companies (i.e. Vanguard Australian Shar...